Similar to some prior reports in primary BC tumors [38, 78], comparison of PAM50 intrinsic subtypes and clinical subtypes in BrM specimens demonstrated considerable heterogeneity between the two means of classifying BC subtypes, though major features like HER2 amplification/enrichment were consistent. Here, ERBB2 is linked to breast cancer.